View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


FDA Grants Priority Review Status for BMS’s Kidney Cancer Combination Therapy

  • December 15, 2017

  • David Leung

    Dr David Leung, Medical Director, Oncology Imaging, Exploratory Clinical & Translational Research, BMS

    Christine Ward

    Dr Christine Ward, Director and Pharmaco-diagnostics Lead – HQ Medical Oncology, BMS

    Congratulations to Immuno-Oncology 360° speakers, Dr Christine Ward, Dr David Leung and their immuno-oncology team at BMS for receiving priority review to an sBLA for Opdivo (nivolumab) plus Yervoy (ipilimumab) to treat intermediate- and poor-risk patients with advanced renal cell carcinoma.

    According to a BioCentury release, the application was supported by the results of a late-stage study in which the combination therapy achieved the primary endpoints of improving the objective response rate and overall survival versus use of Sutent, or sunitinib. The PDUFA date is scheduled for April 16, 2018.

    Dr Christine Ward will be delivering a talk on Tumor Mutation Burden as an Emerging Biomarker and Dr David Leung will be participating on a panel on Operational Aspects for Immunotherapy Imaging at the 4th annual IO360° program taking place February 7-9, 2018 in NYC.

    Learn more information about IO360°.